Literature DB >> 11042511

Structural and functional studies on the leukemia inhibitory factor receptor (LIF-R): gene and soluble form of LIF-R, and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells.

M Tomida1.   

Abstract

The leukemia inhibitory factor receptor (LIF-R) subunit is a component of cell-surface receptor complexes for the multifunctional cytokines, LIF, cardiotrophin-1, ciliary neurotrophic factor, and human oncostatin M. The structure of the human LIF-R gene is similar to that of the mouse gene. The transmembrane receptor is encoded by 19 exons. Two distinct 5' non-coding exons are present, indicating the existence of alternative promoters. An extra-exon specific to the mouse soluble receptor contains a stop codon and polyadenylation signals in a B2 repetitive element. On the other hand, LIF-R mRNAs containing unspliced introns are abundantly present in human tissues. These intronic sequences introduce a termination codon before the transmembrane domain. Human choriocarcinoma cells expressing these mRNAs release soluble LIF-R. The cytoplasmic domain of LIF-R can generate the signals for growth arrest and differentiation of mouse myeloid leukemic cells when they are induced to form a homodimer of the cytoplasmic domain independently of gp130. Two membrane-distal tyrosines on the YXXQ motif of LIF-R are critical not only for STAT3 activation but also for growth arrest and macrophage differentiation of WEHI-3B D+ cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042511     DOI: 10.3109/10428190009058503

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma.

Authors:  Yong Gu Cho; Xiaofei Chang; Il-Seok Park; Keishi Yamashita; Chunbo Shao; Patrick K Ha; Sara I Pai; David Sidransky; Myoung Sook Kim
Journal:  Int J Oncol       Date:  2011-05-23       Impact factor: 5.650

Review 2.  CNTF and retina.

Authors:  Rong Wen; Weng Tao; Yiwen Li; Paul A Sieving
Journal:  Prog Retin Eye Res       Date:  2011-12-10       Impact factor: 21.198

3.  Progressive Differentiation and Instructive Capacities of Amniotic Fluid and Cerebrospinal Fluid Proteomes following Neural Tube Closure.

Authors:  Kevin F Chau; Mark W Springel; Kevin G Broadbelt; Hye-Yeon Park; Salih Topal; Melody P Lun; Hillary Mullan; Thomas Maynard; Hanno Steen; Anthony S LaMantia; Maria K Lehtinen
Journal:  Dev Cell       Date:  2015-12-21       Impact factor: 12.270

4.  Molecular analysis of signaling events mediated by the cytoplasmic domain of leukemia inhibitory factor receptor alpha subunit.

Authors:  Houqi Liu; Shanrong Liu; Shuping Tang; Kaihong Ji; Fengmei Wang; Shijie Hu
Journal:  Mol Cell Biochem       Date:  2004-03       Impact factor: 3.396

5.  Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling.

Authors:  Shu-Chen Liu; Tien Hsu; Yu-Sun Chang; An-Ko Chung; Shih Sheng Jiang; Chun-Nan OuYang; Chiou-Hwa Yuh; Chuen Hsueh; Ya-Ping Liu; Ngan-Ming Tsang
Journal:  Nat Commun       Date:  2018-11-30       Impact factor: 14.919

6.  An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy.

Authors:  Sean A Hunter; Brianna J McIntosh; Yu Shi; R Andres Parra Sperberg; Chie Funatogawa; Louai Labanieh; Erin Soon; Hannah C Wastyk; Nishant Mehta; Catherine Carter; Tony Hunter; Jennifer R Cochran
Journal:  Commun Biol       Date:  2021-04-12

Review 7.  IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment.

Authors:  Carla M Felcher; Emilia S Bogni; Edith C Kordon
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 6.208

8.  Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.

Authors:  Matthias Farlik; Patrick M Brunner; Katharina Rindler; Constanze Jonak; Natalia Alkon; Felix M Thaler; Harald Kurz; Lisa E Shaw; Georg Stingl; Wolfgang Weninger; Florian Halbritter; Wolfgang M Bauer
Journal:  Mol Cancer       Date:  2021-09-28       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.